- OTCMKTS: CYDY stock may surge after reporting significant results from a COVID-19 cure trial.
- CytoDyn is at an advanced stage, completing Phase 2 and may enter Phase 3 with its leronlimab medication.
- Competition is fierce and attention is growing after Russia registered its first coronavirus vaccine.
CytoDyn, a biotechnology company that spans the border between Canada and the US around Vancouver and Washington, announced a promising development. Its Phase 2 trial for COVID-19 has shown significant top-line results, opening the door to conducting a broad Phase 3 trial.
The leronlimab drug helps mild to moderate COVID-19 patients, that show an improvement in clinical symptoms versus the
From the firm's announcement:
Primary endpoint shows early clinical improvement in symptom score at Day 3 in patients receiving leronlimab
Leronlimab also demonstrated statistically significant improvement versus placebo in key secondary efficacy endpoint, National Early Warning Score 2 scale (NEWS2)
Earlier in the day, Russia's President Vladimir Putin announced that his country reported the first coronavirus vaccine. However, many doubt that Moscow's announcement is based on a rigorous experiment.
cytodyn inc Stock
OTCMKTS: CYDY
Reprinted from Fxstreet, the copyright all reserved by the original author.
إخلاء المسؤولية: الآراء الواردة هنا تعبر فقط عن رأي الكاتب، ولا تمثل الموقف الرسمي لـ Followme. لا تتحمل Followme مسؤولية دقة أو اكتمال أو موثوقية المعلومات المُقدمة، ولا تتحمل مسؤولية أي إجراءات تُتخذ بناءً على المحتوى، ما لم يُنص على ذلك صراحةً كتابيًا.
اترك رسالتك الآن